Questions About Hemolytic Disease of the Newborn

Neonatal hemolytic disease (NHD) is a potentially serious condition that occurs when maternal antibodies cross the placenta and attack fetal red blood cells, leading to hemolysis. It most commonly arises from Rh(D) incompatibility—when an Rh-negative mother carries an Rh-positive fetus—or ABO incompatibility, particularly when a group O mother has a group A or B infant. While ABO incompatibility is more frequent, it typically causes milder hemolysis; Rh incompatibility is less common but often more severe, especially in subsequent pregnancies after maternal sensitization.

The pathophysiology centers on transplacental passage of IgG antibodies produced by the mother in response to fetal erythrocyte antigens she lacks. In Rh disease, even small amounts of fetal blood entering maternal circulation during delivery, miscarriage, or invasive procedures can trigger alloimmunization. Once sensitized, the mother produces anti-Rh(D) IgG antibodies that readily cross the placenta in future pregnancies, binding to Rh-positive fetal red blood cells and marking them for destruction by the reticuloendothelial system—primarily in the fetal spleen and liver.

Clinical manifestations range from asymptomatic hyperbilirubinemia to life-threatening complications including severe anemia, hydrops fetalis, kernicterus, and cardiorespiratory decompensation. Early signs may include jaundice within the first 24 hours of life, pallor, hepatosplenomegaly, and lethargy. Laboratory evaluation typically reveals elevated unconjugated bilirubin, decreased hemoglobin, increased reticulocyte count, and a positive direct Coombs test—confirming antibody-coated red blood cells.

Prevention remains the cornerstone of management: administration of intramuscular Rho(D) immune globulin (RhoGAM) to unsensitized Rh-negative mothers at 28 weeks’ gestation and within 72 hours postpartum (or after any potential sensitizing event) reduces the risk of alloimmunization by over 90%. For affected newborns, treatment is tailored to disease severity and may include intensive phototherapy, intravenous immunoglobulin (IVIG), exchange transfusion, and supportive care such as hydration and correction of acidosis or hypoglycemia.

With timely screening—including maternal blood typing, antibody screening, and serial monitoring of antibody titers—and evidence-based interventions, neonatal hemolytic disease is largely preventable and highly treatable. Close collaboration among obstetricians, neonatologists, and transfusion medicine specialists is essential to optimize outcomes for both mother and infant.